false 0000876378 0000876378 2023-06-30 2023-06-30

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

 

 

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

June 30, 2023
Date of Report (date of earliest event reported)

 

 

 

Durham, NC 27703
(Address of principal executive offices)

919-765-8400
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

On February 16, 2023, Asensus Surgical, Inc. (the “Company”) announced that it had entered into a Memorandum of Understanding (“MoU”) with KARL STORZ VentureONE Pte. Ltd. (“KARL STORZ”), a wholly owned subsidiary of KARL STORZ SE & Co. KG to collaborate on developing next-generation instrumentation and an agreement in which KARL STORZ intends to sell the Company’s Intelligent Surgical Unit™ (ISU™) as a standalone device.  The parties had intended to finalize the definitive agreements within 90 days.  As of the date of this current report, the Company and KARL STORZ have not reached agreement on final terms of a definitive agreement.  The timeline to sign a definitive agreement is uncertain.  The Company continues to pursue various collaboration opportunities with other major players in the imaging, visualization and digital surgery space to execute on its strategic plan, including commercialization of a stand-alone ISU. 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.